1. Introduction {#sec1}
===============

With increasing incidence and mortality, cancer has become the leading cause of death and has caused serious public health problems worldwide. Among them, lung cancer is the most common type of cancer \[[@B1], [@B2]\]. Non-small-cell lung cancer (NSCLC) accounts for 80--85% of all lung cancers \[[@B3]\]. At present, the main effective methods in reducing the mortality of non-small-cell lung cancer include chemotherapy, radiotherapy, targeted therapy, and surgery \[[@B4]\]. Nonetheless, the overall 5-year survival rate of NSCLC remains low and is only 18% \[[@B5]\], while the drug resistance and side effects are getting more serious \[[@B2]\]. Therefore, there is an urgent need for novel methods for treating NSCLC that are effective and safe.

In recent years, Traditional Chinese Medicine (TCM) is widely used all over the world. TCM has been effective to relieve complex diseases for over 4000 years due to multicomponent, multitarget, and multilevel characteristics \[[@B6]\]. For instance, compound Liuju formula is widely used in the treatment of lung diseases in China. Clinical medicines such as clinical compound Liuju tablets and compound Liuju granules contain leaves of Hanliuye (*Salix matsudana* Koidz., SMK), Yejuhua (*Chrysanthemum indicum* L., CIL), and Baihuasheshecao (*Hedyotis diffusa* Willd, HDW). The SMK was used in the Chinese dictionary \[[@B7]\] as a traditional anti-inflammatory and analgesic \[[@B7], [@B8]\] medicine. Research has shown that CIL has been used to cure inflammation-related diseases and malignant tumors \[[@B9], [@B10]\]. It is reported that EEHDW has an effective inhibitory activity on human lung cancer cells by inhibiting cell proliferation and reducing cell activity \[[@B11]\]. TCM had fewer side effects, wide availability and better effect, and can availably improve the life quality of NSCLC patients. However, it is very hard to explain the interaction among the collaborative compositions that we confront a huge complex system for TCM formula.

With the development of analytical tools such as biology network \[[@B12]\], network pharmacology \[[@B13]\], and systems biology \[[@B14]\], the complex and comprehensive mechanism of TCM syndrome differentiation is expected to be quickly and efficiently clarified. In previous research, we have successfully constructed a new systems pharmacology method in order to explore the potential mechanism of Traditional Chinese Medicine. This method combines pharmacokinetics (absorption, distribution, metabolism, excretion, and toxicity (ADME/T) characteristics of drugs), molecular evaluation, target prediction, and pathway analysis to explore the effects of drugs \[[@B15], [@B16]\], which provides a platform for identifying multiple mechanisms of action of drugs. This platform has successfully developed four herbs, including Radix *Astragali Mongolici*, Radix *Puerariae Lobatae*, Radix *Ophiopogonis Japonici*, and Radix *Salviae miltiorrhiza* \[[@B17]\], that were applied in the comprehensive treatment of cardiovascular disease. systems pharmacology has become a widely used new tool to reveal the mechanism of drug action and drug development.

In our current work, the systems pharmacology method was utilized to study synergic bioactive compounds isolated from the compound Liuju formula treatment of NSCLC. We screened out bioactive ingredients from the constructed compound Liuju formula via ADME by calculating pharmacokinetic properties and evaluating oral bioavailability (OB) and drug-likeness (DL). Then, a comprehensive target prediction method combining biological model and mathematical model was used to predict the homologous target of the selected bioactive ingredients. Next, the obtained target was verified by functional enrichment analysis and target-disease interaction analysis. Finally, the system revealed potential collaborative interactions between bioactive ingredients, active targets, and pathways through systematic pharmacology theory and NSCLC-related signaling pathway evaluation. And, *in vitro* experiments were conducted to further verify the inhibitory effect of potential bioactive ingredients on tumor cells. These results not only provide new treatments for NSCLC but also promote the elucidation and development of the molecular mechanism of TCM.

2. Materials and Methods {#sec2}
========================

2.1. Construction of Molecular Database and ADME Screening {#sec2.1}
----------------------------------------------------------

All compounds of SMK, CIL, and HDW were obtained from our formerly established database named Traditional Chinese Medicine Systems Pharmacology Database (TCMSP, <http://lsp.nwu.edu.cn/>) \[[@B18]\] and were detected artificially. Because glycosyl molecules are usually hydrolyzed into free glycosides *in vivo*, which can be easily absorbed by intestinal mucosa, we wrote the molecule without glycosyl viscose as \_qt \[[@B19]\]. To gain the bioactive molecules, we employed a comprehensive model comprising predict OB (oral bioavailability) and DL (drug-likeness) to appraise pharmacokinetic and pharmaceutical properties.

### 2.1.1. Oral Bioavailability {#sec2.1.1}

Oral bioavailability (OB) refers to the speed and degree of drug absorption into human circulation, which reflects the proportion of drugs in human circulation and plays a critical role in drug screening. In this work, OB value was calculated by an in-house model OBioavail1.1 \[[@B18]\]. And, the threshold of OB value was positioned as 25% by the following conditions: firstly, get as much information as possible from the herbs studied with the fewest compounds. Secondly, the acquired model is correctly interpreted by the reported pharmacological data \[[@B20]\]. In this work, for further analysis, we limited the OB threshold as 25%.

### 2.1.2. Drug-Likeness {#sec2.1.2}

Drug-likeness (DL) refers to the similarity between compounds and known drugs, which is an important factor in determining the success of final clinical trials of drugs. In this work, we utilized the previously developed internal model (Tanimoto coefficient) \[[@B20]\] to predict drug-like properties of expected molecules. The DL appraisal formula is as follows:$$\begin{matrix}
{T\left( {A,B} \right) = \frac{A \cdot B}{\left| A \right|^{2} + \left| B \right|^{2} - A \cdot B}.} \\
\end{matrix}$$

Among them, *A* represents the molecular descriptor of herbal compounds, and *B* represents the average molecular properties of all compounds in the database (<http://www.drugbank.ca/>) \[[@B21]\]. For further study, we defined DL ≥ 0.18 (average of drug library) as the criterion for screening candidate compounds.

In order to obtain the potential bioactive ingredients, the screening standard was defined as OB ≥ 25%, DL ≥ 0.18.

2.2. Drug Targeting {#sec2.2}
-------------------

In order to structure a direct link between potential bioactive ingredients and targets, we utilized the in-house developed system drug targeting tool (SysDT) \[[@B22]\] and weighted integration similarity (WES) \[[@B23]\] algorithm to predict the target of the compound and to improve the comprehensiveness and accuracy of the target data bank.

Firstly, the weighted ensemble similarity (WES) and systematic drug targeting tool (SysDT) were applied to explore the target information of active compound. As for SysDT, which includes two mathematical tools, Random Forest (RF) and Support Vector Machine (SVM) can determine the interaction between composite targets more completely \[[@B22]\]. There was another computing model, WES, which combines CDK parameters, Dragon parameters, and CDK-Dragon mixing parameters, to predict the direct target of the actual bioactive ingredients \[[@B23]\]. Secondly, the collected protein targets were mapped to the UniProt database (<http://www.uniprot.org>) for standardization \[[@B24]\]. Finally, the normalized compound targets were mapped to Therapeutic Target Database (TTD, <http://database.idrb.cqu.edu.cn/TTD/>) \[[@B25]\], Comparative Toxicogenomics Database (CTD, <http://ctdbase.org/>) \[[@B26]\], Pharmacogenomics Knowledgebase (PharmGKB, <https://www.pharmgkb.org/>) \[[@B27]\], and Kyoto Encyclopedia of Genes and Genomes (KEGG, <http://www.kegg.jp/>) \[[@B28]\] to obtain their corresponding diseases and to screen out a relationship between target and disease network.

2.3. Gene Ontology (GO) Analysis and Pathway Enrichment {#sec2.3}
-------------------------------------------------------

In order to further analyze the specific biological processes and approaches of the potential targets we have obtained, Gene Ontology (GO) enrichment analysis was performed by linking the targets to the KEGG. KEGG is a collection of databases for systematic analysis of gene functions, biological pathways, diseases, drugs, and chemicals \[[@B29]\]. Finally, the pathway and process enrichment analyses were carried out by using Metascape (Metascape, [http://metascape.org](http://metascape.org/)) \[[@B30], [@B31]\] software.

2.4. Network Construction {#sec2.4}
-------------------------

In order to visualize the action mechanism of active compounds treating NSCLC and further clarify the relationship between active targets and compounds, we constructed two relational networks: Compound-Target network (C-T network) and Target-Pathway network (T-P network). In these networks, compounds, targets, and pathways were represented by nodes, while the relationship between them was represented by line segments. The degree represents the number of edges associated with a node, and the larger the number, the more node relationships it represents. The topological properties of these networks were analyzed using Cytoscape 3.6.0 \[[@B32]\], which is fashionable bioinformatics software.

2.5. Pathway Construction {#sec2.5}
-------------------------

In terms of pathway, in order to explore the integrative mechanism of action of compound Liuju formula on NSCLC, an integrated pathway related to NSCLC was established based on existing pathological knowledge of NSCLC. Firstly, in order to obtain the basic information of the pathway, we mapped the screened human target proteins to the KEGG database. Secondly, the integrated KEGG pathways of targets with false discovery rated (FDR) less than 0.05 by Fisher\'s Exact test in the Database for Annotation, Visualization, and Integrated Discovery (DAVID, <http://david.abcc.ncifcrf.gov>) (evaluated to Fisher\'s exact test, FDR \< 0.05) were inspected \[[@B33]\]. Finally, we manually assembled a relatively complete NSCLC-related pathway to further analyze the molecular action mechanism.

2.6. Experimental Detection {#sec2.6}
---------------------------

### 2.6.1. Sample Treatment {#sec2.6.1}

Chemicals apigenin (B20981, HPLC ≥ 98%), kaempferol (B21126, HPLC ≥ 98%), and ursolic acid (B21403, HPLC ≥ 98%) were purchased from Shanghai Yuanye BioTechnology Co., Ltd., (Shanghai, China), and the concentration of the original solution prepared with dimethyl sulfoxide (DMSO) (American, Sigma) was 100 mmol/L. In order to ensure that the survival of cells was not affected, the final concentration of DMSO should not exceed 0.1%.

### 2.6.2. Cell Cultures {#sec2.6.2}

The murine macrophage line RAW264.7 cell and human NSCLC cell lines H1975 cells were obtained from Cell Resource Center, Shanghai Institutes for Biological Sciences, and CAS. RAW264.7 and H1975 cells were cultured in DMEM and RPMI 1640 (Gibco, USA) medium, respectively. Supplemented with 10% heat inactivated foetal bovine serum (FBS) and antibiotics (100 units/mL penicillin and 100 *μ*g/mL streptomycin). Cells were survived in the incubator of 5% CO~2~ at 37°C. Culture medium was changed every other day.

### 2.6.3. Establishment of Inflammation Model {#sec2.6.3}

RAW264.7 cells were used to construct inflammatory models. Firstly, the cells were cultured in 150 mm Petri dish for 24 hours and treated with drugs for 2 hours. Then, 0.1 *μ*g/mL lipopolysaccharide (LPS) was added to culture for 18 hours. Finally, the cells were collected, and the expression level of inflammatory mediators was detected.

### 2.6.4. Cell Cytotoxicity Analysis {#sec2.6.4}

Determination of cell cytotoxicity was conducted by Cell Counting Kit-8 (CCK-8) assay (Best Bio, Shanghai, China). In brief, H1975 cells were cultured in 96-well plates at a density of 1 × 10^5^ cells/well. After 24-hour training, cells were exposed to different concentrations of apigenin, kaempferol, and ursolic acid. After treatment for 48 h, 10 *μ*L of CCK-8 assay was added to each well, and the cells were hatched for 1--4 h at 37°C and 5% CO2. The absorbance value at 550 nm was surveyed using a microplate reader (Molecular Devices, USA). The cell viability was calculated as: OD of treatment/OD of control × 100%.

### 2.6.5. Expression Levels of TNF-*α* and IL-1*β* {#sec2.6.5}

Enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, USA) was used to measure the expression of TNF-*α* and IL-1*β*. The cell supernatant after drug treatment was collected according to the protocol of the specification, and 50 *μ*L of the sample was used for detection. The sample concentration was calculated according to the standards provided in the kit.

2.7. Statistical Analysis {#sec2.7}
-------------------------

Variables were analyzed by Student\'s *t*-test and one-way ANOVA and post hoc analysis of variance (GraphPad Prism version 7). Results were reported as mean values S.E. ^*∗*^*p* \< 0.05; ^*∗∗*^*p* \< 0.01, and ^*∗∗∗*^*p* \< 0.001.

3. Results {#sec3}
==========

3.1. Active Compound Screening {#sec3.1}
------------------------------

To screen out the potential bioactive ingredients of SMK, CIL, and HDW, we appraised the ingredients\' ADME properties including OB and DL. As shown in Supporting Information [](#supplementary-material-1){ref-type="supplementary-material"}, the results showed that among 156 compounds, 37 compounds reached the standard of OB ≥ 25%, DL ≥ 0.18. It was worth noting that 6 shared compounds met the screening conditions of SMK, CIL, or HDW, such as *β*-sitosterol, apigenin, luteolin, kaempferol, ursolic acid, and sitogluside-qt, indicating that these active compounds may exhibit effective pharmacological effects on NSCLC. Further, in order to verify whether virtual screening results were consistent with NSCLC, we conducted a literature review of the potential components. Many of the 37 active components had been reported of having significant antitumor and anti-inflammatory effects. For example, *β*-sitosterol (MOL004, OB = 36.91%, DL = 0.75) induced G0/G1 cell cycle arrest and inhibited cell proliferation in A549 cells \[[@B34]\]. Studies have shown that ursolic acid (MOL074, OB = 37.73%, DL = O.75) induces apoptosis via activation of caspases and phosphorylation of glycogen synthase kinase 3 beta in ovarian cancer cells \[[@B35]\]. Apigenin (MOL009, OB = 45.09, DL = 0.21) was affirmed to inhibit the migration/invasion of NSCLC cells harboring different EGFR statuses via suppressing the Snail/Slug-mediated EMT \[[@B36]\]. These potential compounds may be key components in the treatment of NSCLC.

3.2. Medicine Targeting and Analysis {#sec3.2}
------------------------------------

To explore the target of compounds for NSCLC, we enriched the targets of the compounds. Therefore, we identified 116 targets of these active compounds by means of the WES and SysDT algorithms (as shown in [Table 1](#tab1){ref-type="table"}). The results indicated that most compounds act on more than one target and exhibit multiple pharmacological effects of biologically active molecules. For example, target peroxisome proliferator-activated receptor gamma (PPARG) corresponds to 23 compounds accounting for 62% of the total active compound. Studies have shown that activation of PPARG, *γ* subtype, could cause proliferation inhibition or differentiation of tumor cells \[[@B37]\]. In addition, elevated coexpression of PTGS2 and NOS2 (51% and 48% of the total compounds, respectively) proteins is a strong predictor of poor survival among cancer patients \[[@B38]\]. Hence, these targets involved in the biological processes of NSCLC will be further researched.

3.3. Pathway and Process Enrichment Analyses {#sec3.3}
--------------------------------------------

Next, we used Metacape software to enrich and analyze the gene ontology (GO) of proteins targeting potential bioactive components to verify whether these proteins are related to NSCLC and to set threshold of *P* value ≤0.05. As shown in [Figure 1](#fig1){ref-type="fig"}, we discovered that they all participate in the biological processes such as "cellular response to organic cyclic compound," "inflammatory response," "response to inorganic substance," and "cellular response to nitrogen compound". Thus, the targets of active molecules we filter from the compound Liuju formula could be regarded as the NSCLC therapeutic targets.

3.4. Compound-Target Network Analysis {#sec3.4}
-------------------------------------

In this section, we used Cytoscape 3.6.0 to generate the C-T relation network diagram ([Figure 2](#fig2){ref-type="fig"}) which contains 950 interactions between 37 molecules and 116 targets to reveal the relationship between the target and the compound more directly. Subsequently, the C-T network topology analysis showed that the average degree of the compound was 31 and the average target degree was 8, respectively. This may mean that each active compound is associated with multiple targets and all play key roles in disease mechanisms.

Notably, apigenin (MOL009, Degree = 51) effectively suppressed lung cancer progression by targeting the CD26-Akt-Snail/Slug signaling pathway \[[@B36]\]. And, the research indicated that kaempferol (MOL023, degree = 48) increased tumor cell killing effect through inhibition of the AKT/PI3K and ERK pathways \[[@B39]\]. Also, ursolic acid (MOL047, Degree = 14) was one of the action components that was present in extracts of CIL and HDW. In recent years, anticancer, anti-inflammation, and regulating immune cell effects of ursolic acid have been discovered \[[@B40]--[@B42]\]. Therefore, these three ingredients with a high degree play crucial roles in NSCLC treatment. Significantly, prostaglandin-endoperoxide synthase 2 (PTGS2, Degree = 19) has been found to be highly expressed in many cancer types, and it contributes to tumorigenesis via the inhibition of apoptosis, increased angiogenesis, and invasiveness \[[@B43]\]. All these suggest that compounds probably treat NSCLC by inhibition of tumor cell cycle, anti-inflammation, and inhibiting tumor angiogenesis.

3.5. Target-Pathway Network Analysis {#sec3.5}
------------------------------------

The results are shown in [Table 2](#tab2){ref-type="table"}; the 24 dramatically enriched pathways (*p* value ≤0.05, multiple targets ≥8) may be the main pathway of action and play a key role in NSCLC disease. As shown in [Figure 3](#fig3){ref-type="fig"}, the T-P network includes 88 nodes (64 targets and 24 pathways) and 232 edges. Meanwhile, numerous pathways are regulated by multiple target proteins, which might be the main factor contributing to the anti-NSCLC effect of the herbal formula for NSCLC. pathways in cancer (*p* value = 7.7 *∗* 10^(−12)^, hsa05200, degree = 28), PI3K-Akt signaling pathway (*p* value = 1.0 *∗* 10^(−5)^, hsa04151, degree = 18), MicroRNAs in cancer (*p* value = 1.0 *∗* 10^(−3)^, hsa05206, degree = 13), Proteoglycans in cancer (*p* value = 7.2 *∗* 10^(−4)^, hsa05205, degree = 11), and TNF signaling pathway (*p* value = 1.7 *∗* 10^(−4)^, hsa04668, degree = 9) may be crucial pathways. For instance, the PI3K-AKT pathway may be a key pathway regulating the proliferation and apoptosis of NSCLC cells \[[@B44]\]. Meanwhile, the activation of TNF signaling by inflammatory signaling plays an important role in the development of tumors \[[@B45]\]. Also, heparin sulfate proteoglycans (HSPGs) in the proteoglycans in cancer pathway are key components of the extracellular matrix that mediate cell proliferation, invasion, and cell signaling \[[@B46], [@B47]\]. Therefore, tumor invasion is an important process of tumor growth and metastasis. So, we infer that the compound activates multiple signaling pathways to inhibit inflammation, enhance immune response, and delay invasion of NSCLC. It is noteworthy that the multitarget enrichment of these pathways provides further theoretical support for the treatment of NSCLC.

3.6. NSCLC Disease Pathway Analysis {#sec3.6}
-----------------------------------

To explain the therapeutic mechanism of the active ingredients at the pathway level, based on the target pathway information obtained in the KEGG database, the key pathways obtained from the T-P network analysis were integrated to construct a complete "NSCLC pathway." As shown in [Figure 4](#fig4){ref-type="fig"}, the "NSCLC pathway" includes three signaling pathways, hsa04151: PI3K-Akt signaling pathway, hsa05205: polysaccharide in cancer, and hsa04668: TNF signaling pathway. The integrated pathway reflects multiple modules such as cell proliferation, apoptosis, angiogenesis, and migration.

### 3.6.1. Cell Cycle Progression Module {#sec3.6.1}

PI3K-AKT pathway and TNF signaling pathway are involved in regulating the cell cycle progress. As we mentioned in [Figure 4](#fig4){ref-type="fig"}, apigenin (MOL009) was observed to affect cyclin-dependent kinase 2 (CDK2). It plays a key role in cell cycle progression which could accelerate the transition from G1 to S phase, and the dysregulation of CDK2 is closely related to many cancers \[[@B48]\]. Besides, luteolin (MOL022) was predicted to impact the heat shock protein 90 (HSP90), which regulates DNA methyltransferase transcription and silences tumor suppressor and DNA repair gene methylation in tumor development, growth, and therapeutic response plays an important role \[[@B49]\]. Above results indicate that the compound can effectively regulate the expression of PI3K, CDK/cyclin, GSK3, and other genes, thereby activating the pathway and regulating the cell cycle progression.

### 3.6.2. Inflammation Effects Module {#sec3.6.2}

Inflammatory mediators and inflammatory cells are important components of tumor microenvironment and play an important role in the occurrence, development, and metastasis of tumor \[[@B50]\]. Hence, anti-inflammatory is an integral strategy for the compound treatment. As an important indicator of inflammation, the transcription factor p65 (NF-κB) reduces the expression of the downstream protein prostaglandin G/H synthase 2 (COX-2) and nitric oxide synthase (iNOS) by activated luteolin (MOL022) \[[@B51]\]. Studies have shown that COX2 may be affected by systemic inflammation, and the prognostic impact of COX2 expression depends on tumor characteristics \[[@B52]\]. Also, iNOS is the main mediator of inflammation, and iNOS can enhance inflammation and plays an important role in apoptosis \[[@B53]\]. Therefore, the analysis showed that the compound alleviated the symptoms of inflammatory disorders in patients with NSCLC by regulating the anti-inflammatory activities of NF-κB, cox-2, and iNOS.

### 3.6.3. Invasion Module {#sec3.6.3}

Invasion and metastasis of tumor cells are critical to the development of tumors and exacerbate the progression of tumors. In the "NSCLC pathway" shown in [Figure 4](#fig4){ref-type="fig"}, the polysaccharide in cancer pathway was involved in regulating the invasion and metastasis progress. Research have shown that tumor cells migration was associated with an increase of *αγβ*3 (MOL022, luteolin) integrin proteasome degradation \[[@B54], [@B55]\]. Meanwhile, FGF2, also known as basic fibroblast growth factor (bFGF) and FGF-*β*, is a growth factor and signaling protein encoded by the FGF2 gene. It was involved in a variety of biological processes, including cell growth, tissue repair, angiogenesis, tumor growth, and invasion \[[@B56], [@B57]\]. In addition, VEGFA was modulated by apigenin (MOL009) and luteolin (MOL022). It has been reported in literature that VEGFA has many functions such as increasing vascular permeability, inducing angiogenesis, angiogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis \[[@B58]--[@B60]\]. Thus, these above analyses show that compound may treat NSCLC by regulating the angiogenesis, migration, and invasion.

3.7. *In Vitro* Experimental Detection {#sec3.7}
--------------------------------------

### 3.7.1. Cell Cytotoxicity Assay {#sec3.7.1}

In this section, we used H1975 cell line to verify the compound efficacy. We selected three highly active multitarget components apigenin (MOL009), kaempferol (MOL023) and ursolic acid (MOL047) common to three plants described above for further verification. We used different concentrations of medicine concentration to detect the cytotoxicity of apigenin, kaempferol, and ursolic acid on H1975 and RAW264.7 cell and explored its inhibition rate. The results of cellular cytotoxicity assay (Figures [5(a)](#fig5){ref-type="fig"} and [5(b)](#fig5){ref-type="fig"}) showed that different concentrations of active ingredients significantly inhibited the growth of H1975 and RAW264.7 cells. These results demonstrated that apigenin, kaempferol, and ursolic acid had obvious proliferation inhibition activity on cancer cells.

### 3.7.2. Expression Levels of TNF-*α* and IL-1*β* {#sec3.7.2}

To further confirm the anti-inflammatory activity of apigenin, kaempferol, and ursolic acid, we used RAW264.7 macrophages which were treated by LPS, with or without apigenin, kaempferol, and ursolic acid. Based on previous toxicity results, we chose a dose of 20 *μ*M for further test. Therefore, we examined TNF-*α* and IL-1*β* by ELISA, whose results demonstrated that the apigenin, kaempferol, and ursolic acid can downregulate the levels of TNF-*α*. The combination of drugs is more effective, especially in the three coadministered groups (Figures [5(c)](#fig5){ref-type="fig"} and [5(d)](#fig5){ref-type="fig"}). It is worth noting that the expression of IL-1*β* was not as obvious as TNF-*α*, and the apigenin group was not different from the model group. However, compared with the model group, the expression level of the combined group was significantly reduced. In summary, the results of two groups showed that the combined group was better than the single drug group, and the combination of three drugs was the most obvious one with significant differences.

4. Discussion {#sec4}
=============

With increasing incidence and mortality, lung cancer has become the most common cancer and the leading cause of cancer death \[[@B61]\]. In addition, high metastatic rate of lung cancer and its poor prognosis leading to the search for antilung cancer drugs has become an important issue to be solved.

Hence, in this study, we chose compound Liuju formula, a clinically used Chinese medicine compound, as an example to interpret the combination effect of Traditional Chinese Medicine treatment. In order to further reveal the potential action mechanism of active compounds in Traditional Chinese Medicine formulas, we proposed a systematic pharmacological approach to gain a deeper understanding of the synergistic pharmacological mechanisms of compound Liuju formula. Firstly, based on the evaluation method, 37 active ingredients were obtained, and 116 potential disease-related targets were predicted. The results showed that the compound Liuju formula has the characteristics of multicomponent and multitarget synergistic treatment. Then, active compounds and C-T analysis showed that several active compounds in the compound Liuju formula are essential for the treatment of NSCLC, including apigenin, kaempferol, and ursolic acid. Moreover, some targets such as CDK2, COX2, iNOS, and VEGF have anti-inflammatory, antimigration, and antiproliferation effects on NSCLC. In addition, the result of pathway and process enrichment analyses, T-P analyses, and the integrated "NSCLC pathway" suggest that compound Liuju formula mainly treats NSCLC by regulating cellular process, inflammatory response, migration, and invasion. Finally, we have shown that apigenin, kaempferol, ursolic acid has obvious anti-proliferative effect on lung cancer cells by *in vitro* cytotoxicity test results. Furthermore, we determined by ELISA kit that apigenin, kaempferol, and ursolic acid have significant anti-inflammatory effects, especially in the combination treatment group, confirming the synergistic effect between apigenin, kaempferol, and ursolic acid. The formula has a promoting effect on the regulation of tumor inflammatory microenvironment and has a potential research value in the treatment of NSCLC.

In summary, the systems pharmacology method reveals the characteristics of compound Liuju formula with multicomponent Chinese medicine treatment and multitarget effective treatment. And, this strategy provides a potential method for the rational discovery of new medicines.

However, the current methods of systems pharmacology are still in the early stage of development, and the content of the platform needs to be further enriched. Some models, such as ADME screening, need to be optimized, and some database bases should be expanded and updated. And, developing new algorithms, adding more drug-like properties, and improving screening accuracy could enrich the content of the platform. Moreover, the inhibitory effect on the lung cancer of compound Liuju formula was investigated by us in the study, and then we can carry out systems pharmacology prediction on other diseases and other malignant cancers in in-depth exploration. A more comprehensive therapeutic effect of compound Liuju formula would be developed and may contribute new strategies to cancer therapy.
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Supplementary Figure 1: Graphical Abstract. Table 1: Active constituents and their corresponding ADME parameters.
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Click here for additional data file.

![Pathway and process enrichment analyses of the potential targets. (a) Heatmap of enriched terms across input gene lists, colored by *p* values. (b) Network of enriched terms: colored by cluster ID, where nodes that share the same cluster ID are typically close to each other.](ECAM2019-9854047.001){#fig1}

![Compound-target network. A compound node and a protein node are linked if the protein is targeted by the corresponding compound. Node size is proportional to its degree.](ECAM2019-9854047.002){#fig2}

![Target-pathway network. The T-P network is built by a target and a pathway if the pathway is lighted at the target. Node size is proportional to its degree.](ECAM2019-9854047.003){#fig3}

![The integrated NSCLC pathway for compound Liuju formula.](ECAM2019-9854047.004){#fig4}

![Effect of compound Liuju formula active component at the cellular level. (a, b) Cellular cytotoxicity assay. The *x*-axis shows the drugs concentrations. The *y*-axis shows the inhibition rate of drugs on cells. (c, d) Effect of apigenin, kaempferol, and ursolic acid on LPS-induced production of inflammatory mediators. Expression levels TNF-*α* and IL-1*β* in RAW264.7 cells: experience group cells treated with different dose medicines and analyzed by ELISA. A + K: apigenin and kaempferol; A + U: apigenin and ursolic acid; K + U: kaempferol and ursolic acid; A + K + U: apigenin, kaempferol, and ursolic acid. Data are presented as the mean ± SD (*n* = 3). ^*∗*^*p* \< 0.05, ^*∗∗*^*p* \< 0.01, and ^*∗∗∗*^*p* \< 0.001.](ECAM2019-9854047.005){#fig5}

###### 

The information of disease-related targets.

  UniProt-ID   Protein names                                                                       Gene names   Degree
  ------------ ----------------------------------------------------------------------------------- ------------ --------
  P03372       Estrogen receptor                                                                   ESR1         25
  P04150       Glucocorticoid receptor                                                             NR3C1        13
  P05067       Amyloid-beta A4 protein                                                             APP          15
  P06401       Progesterone receptor                                                               PGR          4
  P06746       DNA polymerase beta                                                                 POLB         4
  P10275       Androgen receptor                                                                   AR           27
  P10636       Microtubule-associated protein tau                                                  MAPT         13
  P11413       Glucose-6-phosphate 1-dehydrogenase                                                 G6PD         13
  P11473       Vitamin D3 receptor                                                                 VDR          13
  P37231       Peroxisome proliferator-activated receptor gamma                                    PPARG        23
  Q08828       Adenylate cyclase type 1                                                            ADCY1        12
  Q13887       Krueppel-like factor 5                                                              KLF5         1
  Q9NYA1       Sphingosine kinase 1                                                                SPHK1        3
  Q9UBM7       7-dehydrocholesterol reductase                                                      DHCR7        14
  P00915       Carbonic anhydrase 1                                                                CA1          6
  P00918       Carbonic anhydrase 2                                                                CA2          17
  P04798       Cytochrome P450 1A1                                                                 CYP19A1      11
  Q07973       1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial                            CYP24A1      5
  Q92731       Estrogen receptor beta                                                              ESR2         18
  O15439       Multidrug resistance-associated protein 4                                           ABCC4        4
  O15118       NPC intracellular cholesterol transporter 1                                         NPC1         4
  Q96RI1       Bile acid receptor                                                                  NR1H4        4
  Q12908       Ileal sodium/bile acid cotransporter                                                SLC10A2      6
  P51449       Nuclear receptor ROR-gamma                                                          RORC         4
  O75751       Solute carrier family 22 member 3                                                   SLC22A3      5
  P04278       Sex hormone-binding globulin                                                        SHBG         5
  Q12772       Sterol regulatory element-binding protein 2                                         SREBF2       4
  P02774       Vitamin D-binding protein                                                           GC           2
  O95622       Adenylate cyclase type 5                                                            ADCY5        13
  P04798       Cytochrome P450 1A1                                                                 CYP1A1       12
  P05091       Aldehyde dehydrogenase, mitochondrial                                               ALDH2        11
  P05177       Cytochrome P450 1A2                                                                 CYP1A2       10
  P07900       Heat shock protein HSP 90-alpha                                                     HSP90AA1     16
  P09917       Arachidonate 5-lipoxygenase                                                         ALOX5        13
  P11309       Serine/threonine-protein kinase pim-1                                               PIM1         15
  P18031       Tyrosine-protein phosphatase non-receptor type 1                                    PTPN1        18
  P19438       Tumor necrosis factor receptor superfamily member 1A                                TNFRSF1A     9
  P23219       Prostaglandin G/H synthase 1                                                        PTGS1        14
  P24941       Cyclin-dependent kinase 2                                                           CDK2         14
  P33527       Multidrug resistance-associated protein 1                                           ABCC1        14
  P35228       Nitric oxide synthase, inducible                                                    NOS2         18
  P35354       Prostaglandin G/H synthase 2                                                        PTGS2        19
  P36888       Receptor-type tyrosine-protein kinase FLT3                                          FLT3         7
  P47989       Xanthine dehydrogenase/oxidase (includes xanthine dehydrogenase)                    XDH          12
  P48736       Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform      PIK3CG       9
  P49841       Glycogen synthase kinase-3 beta                                                     GSK3B        15
  P68400       Casein kinase II subunit alpha                                                      CSNK2A1      4
  Q00534       Cyclin-dependent kinase 6                                                           CDK6         12
  Q12791       Calcium-activated potassium channel subunit alpha-1                                 KCNMA1       4
  Q12882       Dihydropyrimidine dehydrogenase \[NADP(+)\]                                         DPYD         4
  Q16539       Mitogen-activated protein kinase 14                                                 MAPK14       15
  Q16678       Cytochrome P450 1B1                                                                 CYP1B1       14
  Q9BVA1       Tubulin beta-2B chain                                                               TUBB2B       15
  Q9UNQ0       ATP-binding cassette subfamily G member 2                                           ABCG2        13
  Q9Y263       Phospholipase A-2-activating protein                                                PLAA         12
  P00519       Tyrosine-protein kinase ABL1                                                        ABL1         7
  P35869       Aryl hydrocarbon receptor                                                           AHR          8
  O43570       Carbonic anhydrase 12                                                               CA12         18
  P51679       C-C chemokine receptor type 4                                                       CCR4         10
  P13569       Cystic fibrosis transmembrane conductance regulator                                 CFTR         2
  P16220       Cyclic AMP-responsive element-binding protein 1                                     CREB1        12
  P53355       Death-associated protein kinase 1                                                   DAPK1        11
  P60568       Interleukin-2                                                                       IL2          18
  P51812       Ribosomal protein S6 kinase alpha-3                                                 RPS6KA3      11
  P43405       Tyrosine-protein kinase SYK                                                         SYK          4
  Q04760       Lactoylglutathione lyase                                                            GLO1         15
  P08183       Multidrug resistance protein 1                                                      ABCB1        12
  P14174       Macrophage migration inhibitory factor                                              MIF          3
  P15559       NAD(P)H dehydrogenase \[quinone\] 1                                                 NQO1         6
  O14746       Telomerase reverse transcriptase                                                    TERT         11
  P02766       Transthyretin                                                                       TTR          12
  P15692       Vascular endothelial growth factor A                                                VEGFA        17
  P00734       Prothrombin                                                                         F2           9
  P08514       Integrin alpha-IIb                                                                  ITGA2B       2
  P08842       Steryl-sulfatase                                                                    STS          3
  P15090       Fatty acid-binding protein, adipocyte                                               FABP4        2
  P28223       5-hydroxytryptamine receptor 2A                                                     HTR2A        8
  Q16790       Carbonic anhydrase 9                                                                CA9          8
  P05230       Fibroblast growth factor 1                                                          FGF1         7
  P09038       Fibroblast growth factor 2                                                          FGF2         7
  P10145       Interleukin-8                                                                       CXCL8        1
  P09382       Galectin-1                                                                          LGALS1       2
  P17931       Galectin-3                                                                          LGALS3       4
  P01112       GTPase HRas                                                                         HRAS         1
  P14679       Tyrosinase                                                                          TYR          9
  P08253       72 kDa type IV collagenase                                                          MMP2         4
  P08254       Stromelysin-1                                                                       MMP3         4
  P09874       Poly \[ADP-ribose\] polymerase 1                                                    PARP1        2
  P14780       Matrix metalloproteinase-9                                                          MMP9         4
  P24864       G1/S-specific cyclin-E1                                                             CCNE1        4
  P39900       Macrophage metalloelastase                                                          MMP12        4
  O60285       NUAK family SNF1-like kinase 1                                                      NUAK1        6
  P37840       Alpha-synuclein                                                                     SNCA         5
  P11712       Cytochrome P450 2C9                                                                 CYP2C9       3
  P51684       C-C chemokine receptor type 6                                                       CCR6         2
  P27695       DNA-(apurinic or apyrimidinic site) lyase                                           APEX1        4
  P11388       DNA topoisomerase 2-alpha                                                           TOP2A        5
  O60218       Aldo-keto reductase family 1 member B10                                             AKR1B10      9
  P25116       Proteinase-activated receptor 1                                                     F2R          5
  P43681       Neuronal acetylcholine receptor subunit alpha-4                                     CHRNA4       4
  P63151       Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform   PPP2R2A      3
  Q04206       Transcription factor p65                                                            RELA         3
  P14867       Gamma-aminobutyric acid receptor subunit alpha-1                                    GABRA1       3
  P06881       Calcitonin gene-related peptide 1                                                   CALCA        1
  P13501       C-C motif chemokine 5                                                               CCL5         1
  P32245       Melanocortin receptor 4                                                             MC4R         1
  P68104       Elongation factor 1-alpha 1                                                         EEF1A1       3
  Q13822       Ectonucleotide pyrophosphatase/phosphodiesterase family member 2                    ENPP2        3
  Q9Y251       Heparanase                                                                          HPSE         3
  P53985       Monocarboxylate transporter 1                                                       SLC16A1      2
  P11509       Cytochrome P450 2A6                                                                 CYP2A6       3
  Q15788       Nuclear receptor coactivator 1                                                      NCOA1        1
  Q99814       Endothelial PAS domain-containing protein 1                                         EPAS1        3
  P00533       Epidermal growth factor receptor                                                    EGFR         4
  Q16665       Hypoxia-inducible factor 1-alpha                                                    HIF1A        2
  P40926       Malate dehydrogenase, mitochondrial                                                 MDH2         2

###### 

The information of disease-related pathways.

  Term       Pathways                                    Degree
  ---------- ------------------------------------------- --------
  hsa05200   Pathways in cancer                          28
  hsa04151   PI3K-AKT signaling pathway                  18
  hsa05206   MicroRNAs in cancer                         13
  hsa04915   Estrogen signaling pathway                  11
  hsa05205   Proteoglycans in cancer                     11
  hsa04015   Rap1 signaling pathway                      11
  hsa05166   HTLV-I infection                            11
  hsa05215   Prostate cancer                             10
  hsa05142   Chagas disease (American trypanosomiasis)   10
  hsa04062   Chemokine signaling pathway                 10
  hsa05203   Viral carcinogenesis                        10
  hsa04976   Bile secretion                              9
  hsa04668   TNF signaling pathway                       9
  hsa05160   Hepatitis C                                 9
  hsa05161   Hepatitis B                                 9
  hsa04010   MAPK signaling pathway                      9
  hsa05222   Small-cell lung cancer                      8
  hsa04914   Progesterone-mediated oocyte maturation     8
  hsa04726   Serotonergic synapse                        8
  hsa04071   Sphingolipid signaling pathway              8
  hsa04611   Platelet activation                         8
  hsa05162   Measles                                     8
  hsa05152   Tuberculosis                                8
  hsa04024   cAMP signaling pathway                      8
  hsa04810   Regulation of actin cytoskeleton            8

[^1]: Academic Editor: Ho Lin
